Literature DB >> 28717040

Flucloxacillin Results in Suboptimal Plasma Voriconazole Concentrations.

Eline W Muilwijk1,2, Bart G J Dekkers3, Stefanie S V Henriet2,4, Paul E Verweij2,5, Bregje Witjes6, Astrid M L Oude Lashof7, Geert H Groeneveld8, Johannes van der Hoeven9, Jan Willem C Alffenaar3, Frans G M Russel10, Frank van de Veerdonk2,11, Roger J M Brüggemann1,2.   

Abstract

Combining voriconazole and flucloxacillin is indicated in patient cohorts experiencing both invasive aspergillosis and Gram-positive infections (e.g., patients with chronic granulomatous disease or postinfluenza pulmonary aspergillosis). We report a highly relevant interaction between voriconazole and flucloxacillin, resulting in subtherapeutic plasma voriconazole concentrations in more than 50% of patients, that poses a severe threat if not managed properly.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  aspergillosis; drug interactions; exposure; influenza; pharmacokinetics

Mesh：

Substances：

Year:  2017        PMID： 28717040      PMCID： PMC5571297          DOI： 10.1128/AAC.00915-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

1.  CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole.

Authors:  Johanna Weiss; Magdalena Maria Ten Hoevel; Jürgen Burhenne; Ingeborg Walter-Sack; Michael Marcus Hoffmann; Jens Rengelshausen; Walter E Haefeli; Gerd Mikus
Journal:  J Clin Pharmacol       Date:  2008-11-25       Impact factor: 3.126

2.  Interaction between voriconazole and flucloxacillin during treatment of disseminated Scedosporium apiospermum infection.

Authors:  Brendan Kennedy; Rebecca Larcombe; Cassandra Chaptini; David L Gordon
Journal:  J Antimicrob Chemother       Date:  2015-03-15       Impact factor: 5.790

3.  Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes.

Authors:  Norie Murayama; Naoko Imai; Takahisa Nakane; Makiko Shimizu; Hiroshi Yamazaki
Journal:  Biochem Pharmacol       Date:  2007-03-19       Impact factor: 5.858

Review 4.  Pharmacokinetic interactions with rifampicin : clinical relevance.

Authors:  Mikko Niemi; Janne T Backman; Martin F Fromm; Pertti J Neuvonen; Kari T Kivistö
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

5.  In vitro hepatic metabolism explains higher clearance of voriconazole in children versus adults: role of CYP2C19 and flavin-containing monooxygenase 3.

Authors:  Souzan B Yanni; Pieter P Annaert; Patrick Augustijns; Joseph G Ibrahim; Daniel K Benjamin; Dhiren R Thakker
Journal:  Drug Metab Dispos       Date:  2010-01       Impact factor: 3.922

6.  Role of flavin-containing monooxygenase in oxidative metabolism of voriconazole by human liver microsomes.

Authors:  Souzan B Yanni; Pieter P Annaert; Patrick Augustijns; Arlene Bridges; Yan Gao; Daniel K Benjamin; Dhiren R Thakker
Journal:  Drug Metab Dispos       Date:  2008-03-24       Impact factor: 3.922

7.  The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human.

Authors:  S J Roffey; S Cole; P Comby; D Gibson; S G Jezequel; A N R Nedderman; D A Smith; D K Walker; N Wood
Journal:  Drug Metab Dispos       Date:  2003-06       Impact factor: 3.922

8.  Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole.

Authors:  R Hyland; B C Jones; D A Smith
Journal:  Drug Metab Dispos       Date:  2003-05       Impact factor: 3.922

9.  Steady-state pharmacokinetics and metabolism of voriconazole in patients.

Authors:  Marcus J P Geist; Gerlinde Egerer; Jürgen Burhenne; Klaus-Dieter Riedel; Johanna Weiss; Gerd Mikus
Journal:  J Antimicrob Chemother       Date:  2013-06-13       Impact factor: 5.790

Review 10.  Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents.

Authors:  Roger J M Brüggemann; Jan-Willem C Alffenaar; Nicole M A Blijlevens; Eliane M Billaud; Jos G W Kosterink; Paul E Verweij; David M Burger
Journal:  Clin Infect Dis       Date:  2009-05-15       Impact factor: 9.079
  10 in total
  5 in total

Review 1.  Ways to Improve Insights into Clindamycin Pharmacology and Pharmacokinetics Tailored to Practice.

Authors:  Laura Armengol Álvarez; Greet Van de Sijpe; Stefanie Desmet; Willem-Jan Metsemakers; Isabel Spriet; Karel Allegaert; Jef Rozenski
Journal:  Antibiotics (Basel)       Date:  2022-05-21

2.  Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion.

Authors:  Paul E Verweij; Bart J A Rijnders; Roger J M Brüggemann; Elie Azoulay; Matteo Bassetti; Stijn Blot; Thierry Calandra; Cornelius J Clancy; Oliver A Cornely; Tom Chiller; Pieter Depuydt; Daniele Roberto Giacobbe; Nico A F Janssen; Bart-Jan Kullberg; Katrien Lagrou; Cornelia Lass-Flörl; Russell E Lewis; Peter Wei-Lun Liu; Olivier Lortholary; Johan Maertens; Ignacio Martin-Loeches; M Hong Nguyen; Thomas F Patterson; Thomas R Rogers; Jeroen A Schouten; Isabel Spriet; Lore Vanderbeke; Joost Wauters; Frank L van de Veerdonk
Journal:  Intensive Care Med       Date:  2020-06-22       Impact factor: 17.440

3.  Flucloxacillin decreases tacrolimus blood trough levels: a single-center retrospective cohort study.

Authors:  Herman Veenhof; Hugo M Schouw; Martine T P Besouw; Daan J Touw; Valentina Gracchi
Journal:  Eur J Clin Pharmacol       Date:  2020-07-25       Impact factor: 2.953

4.  Interaction between posaconazole and flucloxacillin in a lung transplant patient: decrease in plasma exposure of posaconazole and possible undertreatment of invasive aspergillosis: case report.

Authors:  Saartje Verfaillie; Laurent Godinas; Isabel Spriet; Robin Vos; Geert M Verleden
Journal:  BMC Pulm Med       Date:  2022-03-27       Impact factor: 3.317

5.  Characterization of kinetics of human cytochrome P450s involved in bioactivation of flucloxacillin: inhibition of CYP3A-catalysed hydroxylation by sulfaphenazole.

Authors:  Stefan J Dekker; Floor Dohmen; Nico P E Vermeulen; Jan N M Commandeur
Journal:  Br J Pharmacol       Date:  2018-12-26       Impact factor: 8.739
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.